This convenient kit eliminates the need for mixing tedious buffers, reduces the need to order from multiple vendors, and enables easier inventory management with a single kit expiration date.

Comprised of validated reagents available from Affymetrix and leading reagent suppliers, the SNP 6 Core Reagent Kit is guaranteed to perform to Affymetrix specifications with genomic DNA from blood, saliva, and cell lines, as well as whole-genome-amplified DNA. Additionally, the kit utilizes Affymetrix’ ecologically friendly pouch packaging, which uses recyclable, biodegradable pouches and greatly reduces waste by eliminating the need for boxes.

The new SNP 6 Core Reagent Kit enables our customers to complete their genotyping experiments more quickly and cost effectively without compromising high-quality performance,” said Andy Last, Chief Commercial Officer at Affymetrix. “In addition, our investment in new ‘eco-pouches’ allows labs to save space while helping to promote a cleaner environment.”

The SNP 6 Core Reagent Kit guarantees optimal performance when used with the SNP Array 6.0, which is widely used by researchers on the GeneChip® System 3000 platform for genotyping applications, copy number analysis, and cytogenetics research.

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,000 systems have been shipped around the world and more than 23,000 peer-reviewed papers have been published using the technology.  Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2009, and other SEC reports for subsequent quarterly periods.

NOTE: Affymetrix, the Affymetrix logo, and GeneChip are trademarks or registered trademarks of Affymetrix Inc.

SOURCE: Affymetrix, Inc.